Level C· Early human research exploring benefitsProspective StudyPubMed

Comparison of biological properties of human adipose tissue-derived mesenchymal stem/ stromal cells from healthy and diabetic donors: consequences for cell-based medicinal product development.

Dudek P., Łabędź-Masłowska A., Madeja Z., Zuba-Surma E.

Prospective Study on Osteoarthritis, Type 2 Diabetes, Cardiovascular Disease, published in Cardiovasc Diabetol (2025) — summary generated from the PubMed abstract.

Open my reading list
Level C· Early human research exploring benefitsEvidence level of this study

Early human evidence such as case series or small samples is exploring possible benefits.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Prospective Study
Journal
Cardiovasc Diabetol (2025)
Country
England
Reported sample size
—
Source database
PubMed
PMID
41162998
DOI
10.1186/s12933-025-02943-x

Abstract (original English)

Diabetes mellitus is a civilisation disease that can cause damage to tissues and organs as well as affects the biological properties of cells isolated from these tissues. In recent years, there has been increasing interest in cell-based therapies, including the use of mesenchymal stem/stromal cells (MSCs). Therefore, the aim of the current study was to compare the biological potential of adipose tissue-derived MSCs (AT-MSCs) from healthy and diabetic donors under in vitro conditions and to clarify the implications for cell-based medicinal product development. Biological potential of both populations of AT-MSCs was also investigated in the relation to their major therapeutic mechanisms of action-we focused on the chondrogenic and osteogenic differentiation capacity of AT-MSCs and their pro-angiogenic potential. Human AT-MSCs derived from healthy and type 2 diabetes (T2D) donors underwent biological characterization including assessment of: morphology, viability, antigenic profile, proliferation, presence of senescent cells and oxidative stress, pro-angiogenic properties of AT-MSC secretome as well as trilineage differentiation potential in vitro. AT-MSCs were cultured under the control and diabetes mimicking culture conditions. We observed no significant differences in morphology, viability, expression of MSC markers, proliferation rate, concentration of oxidative stress marker

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.

Evidence level

Early human evidence such as case series or small samples is exploring possible benefits.

How we grade evidence
HumansMesenchymal Stem CellsAdipose TissueCells, CulturedCell DifferentiationDiabetes Mellitus, Type 2OsteogenesisChondrogenesisNeovascularization, PhysiologicCell Proliferation

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research